^
Association details:
| Biomarker: | CCDC6-RET fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Cometriq (cabozantinib capsule) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation
Published date:
12/14/2020
Excerpt:
Taken together, our results demonstrate that cabozantinib is an effective agent in preclinical models harboring RET rearrangements with three different 5’ fusion partners (CCDC6, KIF5B and TRIM33).
DOI:
10.1242/dmm.047779
